CDKN2A and malignant mesothelioma: The combination of BAP1 loss and homozygous p16 (CDKN2A) deletion by FISH and/or MTAP loss has become a cornerstone for distinguishing malignant mesothelioma from reactive mesothelial proliferations, while EZH2 overexpression represents an additional promising marker [166,179,180,181,182,183,184,185].